Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Trillium Therapeutics Inc

CUSIP: 89620X906 | 9 institutional holders

Quarters

Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile